Literature DB >> 22893740

Sentinel versus population-based surveillance of pneumococcal conjugate vaccine effectiveness.

Lee M Hampton1, Elizabeth R Zell, Stephanie Schrag, Adam L Cohen.   

Abstract

OBJECTIVE: To compare sentinel and population-based surveillance of the effect of seven-valent pneumococcal conjugate vaccine (PCV7), introduced in 2000, on the hospitalization of children aged under 5 years with invasive pneumococcal disease (IPD) in the United States of America.
METHODS: Population surveillance data were used to identify children hospitalized between 1998 and 2006 with IPD caused by Streptococcus pneumoniae serotypes. The change from 1998 and 1999 (baseline) to 2006 in the number of hospitalized IPD cases recorded by sentinel surveillance systems involving single hospitals or groups of hospitals was compared with the change in the incidence of hospitalized IPD cases measured by population-based surveillance.
FINDINGS: The change in incidence in the eight surveillance areas varied from -37 to -82% for IPD caused by any serotype and from -96 to -100% for IPD caused by serotypes contained in PCV7. All individual sentinel hospitals with more than three cases annually at baseline reported a decrease in cases by 2006. In addition, over 95% of sentinel systems with an average of more than 30 cases annually at baseline recorded a change by 2006 in the number of cases caused by any serotype that fell within the 95% confidence interval for the change in the incidence of hospitalized cases in the corresponding population surveillance area. The change in cases caused by PCV7 serotypes was accurately measured by 93% and 100% of sentinel systems with ≤ 20 and > 20 cases annually at baseline, respectively.
CONCLUSION: Sentinel surveillance can accurately measure the effect of PCV7 on the number of children hospitalized with IPD, provided sufficient cases are detected at baseline. Serotyping increases accuracy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22893740      PMCID: PMC3417785          DOI: 10.2471/BLT.11.098178

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  28 in total

1.  Pneumococcal conjugate vaccine for childhood immunization--WHO position paper.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2007-03-23

2.  Sequential multiplex PCR for determining capsular serotypes of pneumococci recovered from Brazilian children.

Authors:  Cícero A Dias; Lúcia Martins Teixeira; Maria da Glória Carvalho; Bernard Beall
Journal:  J Med Microbiol       Date:  2007-09       Impact factor: 2.472

3.  Sequential multiplex PCR for identifying pneumococcal capsular serotypes from South-Saharan African clinical isolates.

Authors:  Luis Morais; Maria da Glória Carvalho; Anna Roca; Brendan Flannery; Inacio Mandomando; Montserrat Soriano-Gabarró; Betuel Sigauque; Pedro Alonso; Bernard Beall
Journal:  J Med Microbiol       Date:  2007-09       Impact factor: 2.472

4.  Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study.

Authors:  Richard A Adegbola; Ousman Secka; George Lahai; Nellie Lloyd-Evans; Alpha Njie; Stanley Usen; Claire Oluwalana; Stephen Obaro; Martin Weber; Tumani Corrah; Kim Mulholland; Keith McAdam; Brian Greenwood; Paul J M Milligan
Journal:  Lancet       Date:  2005 Jul 9-15       Impact factor: 79.321

5.  Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.

Authors:  F T Cutts; S M A Zaman; G Enwere; S Jaffar; O S Levine; J B Okoko; C Oluwalana; A Vaughan; S K Obaro; A Leach; K P McAdam; E Biney; M Saaka; U Onwuchekwa; F Yallop; N F Pierce; B M Greenwood; R A Adegbola
Journal:  Lancet       Date:  2005 Mar 26-Apr 1       Impact factor: 79.321

6.  Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa.

Authors:  A von Gottberg; L de Gouveia; S A Madhi; M du Plessis; V Quan; K Soma; R Huebner; B Flannery; A Schuchat; Kp Klugman
Journal:  Bull World Health Organ       Date:  2006-10       Impact factor: 9.408

7.  Active bacterial core surveillance of the emerging infections program network.

Authors:  A Schuchat; T Hilger; E Zell; M M Farley; A Reingold; L Harrison; L Lefkowitz; R Danila; K Stefonek; N Barrett; D Morse; R Pinner
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

Review 8.  Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project.

Authors:  Hope L Johnson; Maria Deloria-Knoll; Orin S Levine; Sonia K Stoszek; Laura Freimanis Hance; Richard Reithinger; Larry R Muenz; Katherine L O'Brien
Journal:  PLoS Med       Date:  2010-10-05       Impact factor: 11.069

9.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

10.  A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

Authors:  Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more
  7 in total

1.  Clinical features and outcomes of invasive pneumococcal disease in a pediatric intensive care unit.

Authors:  Hsiang-Ju Hsiao; Chang-Teng Wu; Jing-Long Huang; Cheng-Hsun Chiu; Yhu-Chering Huang; Jainn-Jim Lin; I-Anne Huang; Oi-Wa Chan; I-Jun Chou; Shao-Hsuan Hsia
Journal:  BMC Pediatr       Date:  2015-07-17       Impact factor: 2.125

2.  Clinical and Environmental Surveillance for Vibrio cholerae in Resource Constrained Areas: Application During a 1-Year Surveillance in the Far North Region of Cameroon.

Authors:  Amanda K Debes; Jerome Ateudjieu; Etienne Guenou; Walter Ebile; Isaac Tadzong Sonkoua; Anthony Chebe Njimbia; Peter Steinwald; Malathi Ram; David A Sack
Journal:  Am J Trop Med Hyg       Date:  2016-01-11       Impact factor: 2.345

3.  Twenty Years of Active Bacterial Core Surveillance.

Authors:  Gayle Langley; William Schaffner; Monica M Farley; Ruth Lynfield; Nancy M Bennett; Arthur Reingold; Ann Thomas; Lee H Harrison; Megin Nichols; Susan Petit; Lisa Miller; Matthew R Moore; Stephanie J Schrag; Fernanda C Lessa; Tami H Skoff; Jessica R MacNeil; Elizabeth C Briere; Emily J Weston; Chris Van Beneden
Journal:  Emerg Infect Dis       Date:  2015-09       Impact factor: 6.883

4.  Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa.

Authors:  Stefano Tempia; Nicole Wolter; Cheryl Cohen; Sibongile Walaza; Claire von Mollendorf; Adam L Cohen; Jocelyn Moyes; Linda de Gouveia; Susan Nzenze; Florette Treurnicht; Marietjie Venter; Michelle J Groome; Shabir A Madhi; Anne von Gottberg
Journal:  BMC Infect Dis       Date:  2015-10-26       Impact factor: 3.090

5.  Integration of enteric fever surveillance into the WHO-coordinated Invasive Bacterial-Vaccine Preventable Diseases (IB-VPD) platform: A low cost approach to track an increasingly important disease.

Authors:  Senjuti Saha; Maksuda Islam; Mohammad J Uddin; Shampa Saha; Rajib C Das; Abdullah H Baqui; Mathuram Santosham; Robert E Black; Stephen P Luby; Samir K Saha
Journal:  PLoS Negl Trop Dis       Date:  2017-10-26

6.  Infectious disease surveillance system descriptors: proposal for a comprehensive set.

Authors:  Julien Beauté; Bruno Christian Ciancio; Takis Panagiotopoulos
Journal:  Euro Surveill       Date:  2020-07

7.  Genome-wide association analyses of invasive pneumococcal isolates identify a missense bacterial mutation associated with meningitis.

Authors:  Yuan Li; Benjamin J Metcalf; Sopio Chochua; Zhongya Li; Hollis Walker; Theresa Tran; Paulina A Hawkins; Ryan Gierke; Tamara Pilishvili; Lesley McGee; Bernard W Beall
Journal:  Nat Commun       Date:  2019-01-14       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.